Insmed (INSM): Take a Deep Breath Before the Earnings Report

Insmed is an American biotechnology company that was the first to bring to market a treatment for bronchiectasis not associated with cystic fibrosis—a severe chronic lung disease. The launch was a resounding success, and management is promising investors sales in the billions. But in recent months, questions have mounted: setbacks in new indications, a pause in the European launch, competitors on the horizon, and the departure of the CFO on the eve of the quarterly report. We’ll break down what’s already priced in and identify the key levels on the chart.